United Therapeutics Corporation (UTHR) Financials

NASDAQ:UTHR

Market Cap

10.36B

Total Revenue

1.94B

Gross Profit

1.79B

Operating Income

979.70M

Net Income

727.30M

Metric	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
revenue	1,116,984,000	1,288,519,000	1,465,761,000	1,598,800,000	1,725,300,000	1,627,800,000	1,448,800,000	1,483,300,000	1,685,500,000	1,936,300,000
costOfRevenue	131,127,000	125,883,000	69,036,000	72,700,000	105,700,000	198,700,000	117,600,000	108,100,000	122,500,000	146,700,000
grossProfit	985,857,000	1,162,636,000	1,396,725,000	1,526,100,000	1,619,600,000	1,429,100,000	1,331,200,000	1,375,200,000	1,563,000,000	1,789,600,000
researchAndDevelopmentExpenses	299,348,000	242,549,000	245,098,000	147,600,000	264,600,000	357,900,000	1,182,600,000	357,700,000	540,100,000	322,900,000
sellingAndMarketingExpenses	--	82,000,000	94,297,000	84,600,000	64,300,000	59,100,000	60,700,000	54,900,000	64,400,000	70,800,000
generalAndAdministrativeExpenses	--	299,287,000	358,315,000	232,200,000	265,800,000	206,700,000	275,500,000	369,000,000	402,600,000	416,200,000
sellingGeneralAndAdministrativeExpenses	394,010,000	381,287,000	452,612,000	316,800,000	330,100,000	265,800,000	336,200,000	423,900,000	467,000,000	487,000,000
operatingExpenses	693,358,000	623,836,000	697,710,000	464,400,000	594,700,000	623,700,000	1,518,800,000	781,600,000	1,007,100,000	809,900,000
operatingIncome	292,499,000	538,800,000	699,015,000	1,061,700,000	814,900,000	805,400,000	-187,600,000	593,600,000	555,900,000	979,700,000
totalOtherIncomeExpensesNet	635,000	3,972,000	350,157,000	2,400,000	-246,400,000	-61,200,000	22,600,000	45,300,000	38,000,000	-29,100,000
ebitda	296,961,000	542,772,000	699,172,000	1,064,100,000	1,038,100,000	826,300,000	-120,800,000	671,500,000	614,800,000	984,700,000
depreciationAndAmortization	31,259,000	32,245,000	32,921,000	31,600,000	31,000,000	35,900,000	66,800,000	77,900,000	58,900,000	5,000,000
interestIncome	3,827,000	--	--	--	--	28,600,000	44,200,000	28,600,000	16,700,000	45,200,000
interestExpense	18,058,000	17,592,000	4,735,000	3,900,000	9,000,000	13,900,000	44,200,000	23,500,000	18,600,000	32,400,000
incomeBeforeTax	278,903,000	525,180,000	1,044,437,000	1,060,200,000	769,500,000	758,900,000	-165,000,000	638,900,000	593,900,000	950,600,000
incomeTaxExpense	104,343,000	185,106,000	392,798,000	346,500,000	351,600,000	169,700,000	-60,500,000	124,100,000	118,100,000	223,300,000
netIncome	174,560,000	340,074,000	651,639,000	713,700,000	417,900,000	589,200,000	-104,500,000	514,800,000	475,800,000	727,300,000
eps	3.49	7.06	14.17	16.29	9.5	13.54	-2.39	11.65	10.6	15.98
epsdiluted	3.28	6.28	12.72	15.25	9.31	13.39	-2.39	11.54	10.06	15
weightedAverageShsOut	50,076,000	48,176,000	46,000,000	43,800,000	44,000,000	43,500,000	43,800,000	44,200,000	44,900,000	45,500,000
weightedAverageShsOutDil	53,231,000	54,155,000	51,221,000	46,800,000	44,900,000	44,000,000	43,800,000	44,600,000	47,300,000	48,500,000
costAndExpenses	824,485,000	749,719,000	766,746,000	537,100,000	700,400,000	822,400,000	1,636,400,000	889,700,000	1,129,600,000	956,600,000
otherExpenses	635,000	3,972,000	157,000	2,400,000	13,200,000	-7,700,000	22,600,000	49,300,000	42,200,000	-40,200,000

Key Facts

Industry

Biotechnology

Sector

Healthcare

Headquarters

Silver Spring, MD, US

Website

unither.com

CEO

Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.

Employees

985

About the Company

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.